Mabylon AG
Chiara Arena is a Senior Scientist Antibody Discovery at Mabylon AG since April 2017. Prior to this, Chiara worked as a Research Assistant at Universität Bern, focusing on biochemical and functional characterization of synthetic small-molecules in small molecules drug discovery projects. Chiara holds a Ph.D. in Medicinal and Pharmaceutical Chemistry from Università di Pisa and also completed their Master's degree in the same field at the same university.
This person is not in any teams
Mabylon AG
Mabylon AG, a private Swiss biotech company, is leading innovation in antibody-based treatments for severe allergies, inflammation, and neurological disorders. Our B-cell screening platform identifies natural human antibodies with high specificity and therapeutic potential. MY006, our first-in-class multispecific antibody therapeutic for peanut allergy, is tackling the growing food allergy market.